Ask ten surgeons which tamponade to use in retinal detachment repair and you will get ten different answers. Ahead of his Ingrid Kreissig Lecture at the Euretina Congress in Vienna, David Steel joins Jens Kiilgaard to ask why the evidence base is still so thin, what our gases really cost the environment, and why he believes a revolution in tamponades is coming.
Ahead of his Ophthalmologica Lecture at the Euretina Congress in Vienna, Elon van Dijk joins Ophthalmologica Editor-in-Chief Martin Zinkernagel to explain why central serous chorioretinopathy remains so hard to pin down — and what multimodal imaging can tell us about which eyes will resolve on their own. They discuss the evidence behind half-dose PDT, the trials that got us there, and the career choices behind the lecture
Ahead of her Gisbert Richard Lecture at the Euretina Congress in Vienna, Noemi Lois tells Nicole Eter why diabetic tractional retinal detachment is far more than a mechanical problem — and why we may be catching patients too late. They discuss the scarce evidence on risk factors, anti-VEGF before vitrectomy, tamponade choices, and what the EMERALD study means for clinic capacity.
Ahead of his Euretina Lecture in Vienna — “The Dark Side of the Moon: New Horizons in Dry AMD” — Past President Frank Holz joins President Nicole Eter for a wide-ranging conversation on his career, from pioneering retinal imaging to restoring central vision in advanced AMD, and why dry AMD may finally be at a turning point. Catch the lecture live in Vienna on Thursday 1 October.
In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Bahram Bodaghi is joined by Elisabetta Miserocchi and Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids
The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Anat Loewenstein, Nicole Eter and Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA’s Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can’t offer
Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Kanmin Xue chairs a global discussion with Domenico Lepore, Wei-Chi Wu and Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn’t yet answered.
A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Emine Kiliç chairs a multidisciplinary discussion with Iwona Rospond-Kubiak, Antonia Joussen and radiation oncologist Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.
Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr. Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what’s new and why participation from the whole community – women and men alike – is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.
New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.
A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches.
Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists
Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future.
Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Aude Couturier, Edoardo Midena, and Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema.
What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker, Sascha Fauser, and Marion Munk about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics
IMPORTANT INFORMATION